title: Phacilitate Barcelona active immunotherapeutics forum. 11-13 May 2011, Barcelona, Spain.
abstract: The era of active immunotherapy has now been successfully ushered into the clinical realm of advanced prostate cancer. The successful clinical trial development and US FDA approval of sipuleucel-T (Provenge®) has revamped the therapeutic paradigm for advanced prostate cancer. Nonetheless, physician and patient education as well as regulatory pathways and manufacturing efficiencies are still required in order to optimize patient care. These topics were covered at the Phacilitate Barcelona Active Immunotherapeutics Forum.
authors.affiliation: Carolina Urologic Research Center/Atlantic Urology Clinics, Myrtle Beach, SC 29572, USA. nshore@grandstrandurology.com
authors.forename: Neal D
authors.initials: ND
authors.lastname: Shore
mesh_terms: D000486:Allergy and Immunology; D000818:Animals; D001709:Biotechnology; D019496:Cancer Vaccines; D002986:Clinical Trials as Topic; D006801:Humans; D007167:Immunotherapy / Q000639:trends; D010353:Patient Education as Topic; D013030:Spain; D057170:Translational Research, Biomedical
chemical_list: D019496:Cancer Vaccines